England OKs Routine Funding For Three COVID-19 Treatments But Rejects Five Others

 
• By Neena Brizmohun

The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.

Immunological system, antibodies attacking the virus covid-19.
NICE wants feedback on its draft guidance on COVID-19 treatments • Source: Alamy

More from United Kingdom

More from Europe